Correlation Between Xbrane Biopharma and Cyxone AB

Can any of the company-specific risk be diversified away by investing in both Xbrane Biopharma and Cyxone AB at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Xbrane Biopharma and Cyxone AB into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Xbrane Biopharma AB and Cyxone AB, you can compare the effects of market volatilities on Xbrane Biopharma and Cyxone AB and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Xbrane Biopharma with a short position of Cyxone AB. Check out your portfolio center. Please also check ongoing floating volatility patterns of Xbrane Biopharma and Cyxone AB.

Diversification Opportunities for Xbrane Biopharma and Cyxone AB

-0.04

Correlation Coefficient

Xbrane Biopharma  Cyxone AB

Good diversification

The 3 months correlation between Xbrane and Cyxone is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding Xbrane Biopharma AB and Cyxone AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cyxone AB and Xbrane Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Xbrane Biopharma AB are associated (or correlated) with Cyxone AB. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cyxone AB has no effect on the direction of Xbrane Biopharma i.e., Xbrane Biopharma and Cyxone AB go up and down completely randomly.

Pair Corralation between Xbrane Biopharma and Cyxone AB

Assuming the 90 days trading horizon Xbrane Biopharma AB is expected to generate 0.44 times more return on investment than Cyxone AB. However, Xbrane Biopharma AB is 2.25 times less risky than Cyxone AB. It trades about 0.06 of its potential returns per unit of risk. Cyxone AB is currently generating about -0.02 per unit of risk. If you would invest  15.00  in Xbrane Biopharma AB on September 12, 2024 and sell it today you would earn a total of  2.00  from holding Xbrane Biopharma AB or generate 13.33% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.46%
Values	Daily Returns

Xbrane Biopharma AB  vs.  Cyxone AB

Xbrane Biopharma

Risk-Adjusted Performance

4 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Xbrane Biopharma AB are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Xbrane Biopharma sustained solid returns over the last few months and may actually be approaching a breakup point.

Cyxone AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cyxone AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Xbrane Biopharma and Cyxone AB

The main advantage of trading using opposite Xbrane Biopharma and Cyxone AB positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Xbrane Biopharma position performs unexpectedly, Cyxone AB can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyxone AB will offset losses from the drop in Cyxone AB's long position.

The idea behind Xbrane Biopharma AB and Cyxone AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.